A New Approach to Cancer Treatment Through Programmed Cell Death (Apoptosis)

The ultimate aim of the methods we use in cancer treatment is to trigger tumor cells' death mechanisms, and apoptosis (programmed cell death) is one of these mechanisms. However, many cancer types produce large amounts of proteins that prevent apoptosis. Escaping apoptosis is one of the 10 hallmarks of cancer. These are called inhibitors of apoptosis proteins (IAP).

Debio 1143 is an orally available drug candidate that, by reducing the activity of proteins that inhibit apoptosis, sensitizes tumor cells to chemoradiotherapy (chemotherapy with concurrent radiotherapy) and immunotherapy, thereby strengthening treatment effectiveness. Detailed studies show that Debio 1143 not only activates apoptosis but also enhances the activity of antitumor T lymphocytes, helping produce a stronger immune response. Mouse-model studies found that using Debio 1143 with immune checkpoint inhibitors (such as nivolumab or other anti-PD-L1 agents) significantly reduced tumor volume, demonstrating greater success with treatments combining multiple agents.

Phase-2 study

Debio 1143 had shown effectiveness in breast and colon cancer models. To determine its effectiveness in head and neck cancers, researchers enrolled previously untreated patients within a specified age range diagnosed with squamous cell head and neck cancer. Patients were divided into two groups: one received standard treatment plus placebo, while the other also received Debio 1143. Both groups received high-dose cisplatin chemoradiotherapy.

In patient groups followed for 24 months after treatment ended, in the group receiving Debio 1143, progression-free survival and overall survival rates have not yet been reported because more than half the patients continue responding to treatment. However, a statistically significant difference between the groups is reported, with Debio 1143 increasing the antitumor effectiveness of standard chemoradiotherapy.

Debio 1143 increases treatment effectiveness in the high-risk patient group by inhibiting proteins that prevent apoptosis, while also not changing the effectiveness of high-dose cisplatin or radiotherapy. Its side effects are described as manageable. Phase 2 clinical trial results have been published, and the researchers state that they will move to phase 3, aiming to identify a new treatment option.

Conclusion

Beyond head and neck cancer, Debio 1143 effectiveness is also being tested in clinical trials for small-cell lung cancer, gastrointestinal cancers, platinum-resistant ovarian cancer, uterine cancer, peritoneal cancer (cancer of the abdominal lining) and other solid (organ) tumors such as cervical cancer. Published study results are extremely exciting and promising. The United States Food and Drug Administration (FDA) also supports and provides grants for research in this field. Future positive findings could pave the way for Debio 1143 use not only with immune checkpoint inhibitors but also with other immunotherapy methods, and help us overcome the treatment resistance frequently encountered in solid tumors.